Analysis of multiple factors related to hematologic toxicity following 153Sm-EDTMP therapy.
OBJECTIVE
The aim of this study was to investigate the clinical factors related to hematologic toxicity caused by treatment with samarium-153 ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP).


METHODS
A total of 206 secondary bone neoplasm patients treated with 153Sm-EDTMP were analyzed retrospectively. Logistic regression (SPSS 10.0 for Windows; Chicago, IL) and correlation analysis were used to evaluate the factors concerned.


RESULTS
Age, number of bone metastatic lesions, chemotherapy before treatment with 153Sm-EDTMP, concurrence of radiotherapy, and times of repeated treatments with 153Sm-EDTMP were determined by single factor analysis to be related to hematologic toxicity. Chemotherapy before treatment with 153Sm-EDTMP, concurrence of radiotherapy, drug use to maintain normal white blood cell counts, and times of repeated treatments with 153Sm-EDTMP were determined by multiple factor analysis to be related to hematologic toxicity.


CONCLUSIONS
Chemotherapy before treatment with 153Sm-EDTMP, concurrence of radiotherapy, drug use to maintain normal white blood cell counts, and times of repeated treatments with 153Sm-EDTMP are the main clinical factors related to hematologic toxicity caused by 153Sm-EDTMP therapy. In patients with such factors, more attention might be paid to the change of blood cell counts after 153Sm-EDTMP therapy.
Liu
Hongbiao
H
Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, People's Republic of China.
Zhan
Hongwei
H
Sun
Da
D
Xu
Wei
W
Ye
Xiaojuan
X
Zhang
Hong
H
Zhao
Chunlei
C
Bao
Chengkan
C
He
Gangqiang
G
Yin
Feng
F
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies